23 November 2023 - Ghent ICC

Since the approval of the first CAR-T therapy in blood cancer in 2017, autologous CAR-T therapy (i.e. based on a patient’s own cells) has proven to be highly effective and has great potential to save lives around the world. Despite this progress, the unmet need remains high as still many cancer patients relapse, are resistant to treatment, have rare and/or aggressive tumors or receive late diagnosis. From a clinical point of view, multi-targeting (multi-specific, multi-paratopic) CAR-T products have the potential to create more durable and deeper responses. From an access point of view, only 10 to 20 percent of eligible patients can benefit from current CAR-T therapy, due to capacity constraints and long and complex supply chains. At Galapagos, we think that that a new delivery model for CAR T-cell therapies can be achieved to address the current limitations of cell therapy treatments that prevent broad access to such treatments for cancer patients. With Galapagos’ novel point-of-care delivery model, which takes cell therapy manufacturing to hospitals or facilities nearby, close to patients. With novel science, out of the box supply chain thinking, and smart engineering, we believe in the potential for a shift in the CAR-T treatment paradigm in blood cancer.